Top ▲
Target id: 2075
Nomenclature: mitogen-activated protein kinase kinase kinase 15
Abbreviated Name: MAP3K15
Family: STE11 family
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 1313 | Xp22.12 | MAP3K15 | mitogen-activated protein kinase kinase kinase 15 | |
Mouse | - | 1331 | X F4 | Map3k15 | mitogen-activated protein kinase kinase kinase 15 | |
Rat | - | - | Xq21 | Map3k15 | mitogen-activated protein kinase kinase kinase 15 |
Previous and Unofficial Names |
apoptosis signal-regulating kinase 3 | ASK3 |
Database Links | |
Alphafold | Q6ZN16 (Hs), A2AQW0 (Mm) |
BRENDA | 2.7.11.25 |
ChEMBL Target | CHEMBL1163127 (Hs) |
Ensembl Gene | ENSG00000180815 (Hs), ENSMUSG00000031303 (Mm), ENSRNOG00000025290 (Rn) |
Entrez Gene | 389840 (Hs), 270672 (Mm), 501558 (Rn) |
Human Protein Atlas | ENSG00000180815 (Hs) |
KEGG Enzyme | 2.7.11.25 |
KEGG Gene | hsa:389840 (Hs), mmu:270672 (Mm), rno:501558 (Rn) |
OMIM | 300820 (Hs) |
Pharos | Q6ZN16 (Hs) |
RefSeq Nucleotide | NM_001001671 (Hs), NM_001163085 (Mm) |
RefSeq Protein | NP_001001671 (Hs), NP_001156557 (Mm) |
UniProtKB | Q6ZN16 (Hs), A2AQW0 (Mm) |
Wikipedia | MAP3K15 (Hs) |
Enzyme Reaction | ||||
|
DiscoveRx KINOMEscan® screen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform. http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan Reference: 1-2 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target used in screen: MAP3K15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Displaying the top 10 most potent ligands View all ligands in screen » |
1. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]
2. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]
STE11 family: mitogen-activated protein kinase kinase kinase 15. Last modified on 18/08/2014. Accessed on 11/11/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=2075.